Patent intelligence · US
US 11447537
PDL2 compounds
PDL2 compounds
Patent details — US 11447537
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 20, 2022
- Expiration
- Sep 15, 2042
- Applicant
- IO Biotech ApS
- Claims
- 8
- CPC classes
- A61K, A61K38/00, A61K39/39, A61K40/11
Quick answer
US 11447537 (PDL2 compounds) is held by IO Biotech ApS. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IO Biotech ApS
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K38/00, A61K39/39, A61K40/11, A61K40/421, A61K45/06
More from IO Biotech ApS
Related pharmaceutical patents in our USPTO index.
-
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12215135
PDL2 compounds
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 12077785
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
granted -
US 11981944
Immunogenic arginase peptides
granted -
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
granted
Related coverage
Medicare price rule could hit Keytruda and Opdivo subcutaneous launches
CMS is proposing a Medicare drug price rule that could shape the outlook for subcutaneous Keytruda and Opdivo. The products are expected to be eligible for selection in the 2027 negotiation round for IPAY 2029.
FDA approves belzutifan plus pembrolizumab for adjuvant RCC
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. The catalyst is based on phase 3 LITESPARK-022 data and adds another regulatory milestone for belzutifan.
FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC
The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma. The move extends Merck’s renal cancer catalyst path after evidence showed improved disease-free survival versus pembrolizumab alone.
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.
Frequently asked questions
What is US patent 11447537?
US 11447537 (PDL2 compounds) is held by IO Biotech ApS. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11447537?
IO Biotech ApS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 11447537 expire?
Our index shows an expiration date of Sep 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.